Phase 1 study of glutaminase (GLS) inhibitor CB-839 combined with either everolimus (E) or cabozantinib (Cabo) in patients (pts) with clear cell (cc) and papillary (pap) metastatic renal cell cancer (mRCC) Meeting Abstract

  

Authors:	Tannir, N. M.; Fan, A. C.; Lee, R. J.; Carthon, B. C.; Iliopoulos, O.; Mier, J. W.; Patel, M. R.; Meric-Bernstam, F.; DeMichele, A.; Voss, M. H.; Harding, J. J.; Srinivasan, R.; Shapiro, G.; Telli, M. L.; Munster, P. N.; Carvajal, R. D.; Jenkins, Y.; Whiting, S. H.; Bendell, J. C.; Bauer, T. M.
Abstract Title:	Phase 1 study of glutaminase (GLS) inhibitor CB-839 combined with either everolimus (E) or cabozantinib (Cabo) in patients (pts) with clear cell (cc) and papillary (pap) metastatic renal cell cancer (mRCC)
Meeting Title:	2018 Genitourinary Cancers Symposium
Journal Title:	Journal of Clinical Oncology
Volume:	36
Issue:	6 Suppl.
Meeting Dates:	2018 Feb 8-10
Meeting Location:	San Francisco, CA
ISSN:	0732-183X
Publisher:	American Society of Clinical Oncology
Date Published:	2018-02-20
Language:	English
ACCESSION:	WOS:000436179500597
DOI:	10.1200/JCO.2018.36.6_suppl.603
PROVIDER:	wos
Notes:	Meeting Abstract: 603 -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/137341